Sugi Predict

Sugi Predict / Compounds / SCHEMBL4462839

SCHEMBL4462839

SCHEMBL4462839

Cc1c(Sc2ccc(=O)[nH]n2)oc2ccc(Cl)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 11/20 0.60
▸ MCL1 Q07820 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.38
▸ NOTUM Q6P988 1/20 0.38
▸ ADCY1 Q08828 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ CDC7 O00311 1/20 0.36
▸ DYRK3 O43781 1/20 0.36
▸ IGF1R P08069 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ CLK2 P49760 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ CSNK2A1 P68400 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ PKN2 Q16513 1/20 0.36
▸ PIM3 Q86V86 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ PIM2 Q9P1W9 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167578 0.77 MCL1 (0.43) AKR1B1MCL1ADORA3ADCY1KCNH2
SCHEMBL6176631 0.75 MCL1 (0.44) AKR1B1MCL1ADORA3ADCY1KCNH2
SCHEMBL690925 0.75 AKR1B1 (1.00) AKR1B1
SCHEMBL30977156 0.75 AKR1B1 (1.00) AKR1B1
SCHEMBL4453848 0.74 MCL1 (0.40) AKR1B1MCL1ADORA3ADCY1KCNH2
SCHEMBL4449406 0.72 MCL1 (0.41) AKR1B1MCL1ADORA3ADCY1KCNH2
SCHEMBL4454496 0.71 AKR1B1 (0.55) AKR1B1MCL1ADORA3NOTUMADCY1
SCHEMBL4455159 0.70 AKR1B1 (0.67) AKR1B1
SCHEMBL6206104 0.69 NOTUM (0.59) AKR1B1NOTUMKMT2AALDH1A1POLB
SCHEMBL4451833 0.65 AKR1B1 (1.00) AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1491540-B1 Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2006-12-13 — — EP claimed
US-6849629-B2 Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders PFIZER, INC. (US) 2005-02-01 — — US claimed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 — — US claimed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 — — US claimed
US-7572910-B2 Pyridazinone aldose reductase inhibitors PFIZER, INC. (US) 2009-08-11 — — US disclosed
EP-1491541-B1 Pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2007-01-24 — — EP disclosed
EP-1491540-B1 Intermediates useful for the synthesis of pyridazinone aldose reductase inhibitors PFIZER PROD INC (US) 2006-12-13 — — EP disclosed
EP-1463725-B1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PROD INC (US) 2005-08-17 — — EP disclosed
US-20050113381-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2005-05-26 — — US disclosed
US-6849629-B2 Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders PFIZER, INC. (US) 2005-02-01 — — US disclosed
US-20050004124-A1 THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS MYLARI BANAVARA L (US) 2005-01-06 — — US disclosed
EP-1373259-B1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PROD INC (US) 2004-12-29 — — EP disclosed
EP-1373259-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS Pfizer Products Inc. (US) 2004-01-02 — — EP disclosed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 — — US disclosed
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents TOM NORMA J (US) 2003-08-28 — — US disclosed
WO-2003057691-A1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2003-07-17 — — WO disclosed
US-6579879-B2 Pyridazinone aldose reductase inhibitors PFIZER INC 2003-06-17 — — US disclosed
WO-2002087584-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 — — WO disclosed
WO-2002079198-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-10-10 — — WO disclosed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113381-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 AKR1B1 3/4885MCL1 4625/4885ADORA3 99/4885
US-20030162784-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 AKR1B1 3/4885MCL1 4625/4885ADORA3 99/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 AKR1B1 2/4885MCL1 4705/4885ADORA3 152/4885
US-20050004124-A1 THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS ALDOA, AKR1B1, ALDH2 AKR1B1 2/4885MCL1 3910/4885ADORA3 1357/4885
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents ALDOA, AKR1B1, DPYD AKR1B1 2/4885MCL1 4399/4885ADORA3 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.